Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2304854/bristol-myers-squibb-bmy-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2304854
Jul 18, 2024 - The latest trading day saw Bristol Myers Squibb (BMY) settling at $42.39, representing a -1.76% change from its previous close.
0
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
https://www.zacks.com/stock/news/2300330/bristol-myers-squibb-bmy-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2300330
Jul 11, 2024 - In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $40.75, denoting a -0.9% change from the preceding trading day.
0
3 High-Yield S&P 500 Dividend Stocks That You Can Buy With $100 Right Now
https://www.fool.com/investing/2024/07/09/3-high-yield-sp-500-dividend-stocks-that-you-can-b/?source=iedfolrf0000001
Jul 09, 2024 - After underperforming the benchmark index these stocks offer high dividend yields that are hard to ignore.
0
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2293172/bristol-myers-squibb-bmy-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2293172
Jun 25, 2024 - In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
0
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
https://www.zacks.com/stock/news/2292466/bristol-myers-bmy-krazati-gets-fda-nod-for-colorectal-cancer?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2292466
Jun 24, 2024 - Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
0
3 No-Brainer Stocks to Buy for Under $100 Right Now
https://www.fool.com/investing/2024/06/22/3-no-brainer-stocks-to-buy-for-under-100-right-now/?source=iedfolrf0000001
Jun 22, 2024 - You won't need much money to start investing in these great stocks.
0
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
https://www.fool.com/investing/2024/06/15/3-high-yield-sp-500-dividend-stocks-down-more-than/?source=iedfolrf0000001
Jun 15, 2024 - Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily.
0
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
https://www.zacks.com/stock/news/2288701/bristol-myers-bmy-gets-fda-nod-for-label-expansion-of-augtyro?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2288701
Jun 14, 2024 - The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
0
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
https://www.zacks.com/stock/news/2286219/geron-gern-wins-fda-approval-for-blood-cancer-drug-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2286219
Jun 10, 2024 - Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
0
Replimune (REPL) Gains on Positive Data From Melanoma Study
https://www.zacks.com/stock/news/2285366/replimune-repl-gains-on-positive-data-from-melanoma-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2285366
Jun 07, 2024 - Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.
0